🇺🇸 Teriparatide (Forteo) in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Abnormal Sensation In Eye — 1 report (10%)
- Arthropathy — 1 report (10%)
- Back Pain — 1 report (10%)
- Epistaxis — 1 report (10%)
- Erythema — 1 report (10%)
- Gait Disturbance — 1 report (10%)
- Genital Erythema — 1 report (10%)
- Headache — 1 report (10%)
- Hypoaesthesia — 1 report (10%)
- Increased Tendency To Bruise — 1 report (10%)
Teriparatide (Forteo) in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Teriparatide (Forteo) approved in United States?
Teriparatide (Forteo) does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Teriparatide (Forteo) in United States?
M.D. Anderson Cancer Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.